AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Akeso, Inc.
HKD 95.25
-$18.05 (-15.93%)
HKSE · 15 Sep 2026 08:08 UTC
Previous Close
HKD 95.7
Day Range
HKD 93.6HKD 96.4
Year Range
HKD 80.2HKD 156
Market Cap
87.63B
AVG Volume
13.19M
Trailing/Forward PE
-78.33/78.11
PEG ratio
0.11
Dividend Yield
-
Next Earnings Date
2027-03-31
Primary Exchange
Hong Kong Stock Exchange
Video analysis: 9926.HK
All videosNo video analysis for this stock yet. Request one from our team.
News: 9926.HK
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that a pre-specified interim analysis of overall survival (OS) in the
Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC
/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study
Similar companies
-
Sino Biopharmaceutical Limited
1177.HK
·
Hong Kong Stock Exchange
Compare
-
3SBio Inc.
1530.HK
·
Hong Kong Stock Exchange
Compare
-
TransThera Sciences (Nanjing). Inc.
2617.HK
·
Hong Kong Stock Exchange
Compare
-
Innovent Biologics, Inc.
1801.HK
·
Hong Kong Stock Exchange
Compare
-
WuXi Biologics (Cayman) Inc.
2269.HK
·
Hong Kong Stock Exchange
Compare
-
RemeGen Co., Ltd.
9995.HK
·
Hong Kong Stock Exchange
Compare